Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir + emtricitabine/tenofovir alafenamide in treatment-naive adults with HIV-1
2015-003988-10Phase 3Unknown
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Bictegravir/emtricitabine/tenofovir alafenamide with Dolutegravir + emtricitabine/tenofovir alafenamide (2 arms). Primary endpoint: Proportion of subjects with HIV-1 RNA less than 50 copies/mL at Week 48. Status: unknown.
02
Drugs
bictegraviremtricitabinetenofovir alafenamidedolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-003988-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003988-10.